Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 6Mouth Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Carcinoma 4Oropharyngeal Neoplasms 3Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 17Leucovorin 13Fluorouracil 13Cetuximab 12Bevacizumab 10pembrolizumab 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 6Irinotecan 6Capecitabine 6encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4fludarabine 3cemiplimab 3Laparoscopy 3Folfox protocol 3Early Intervention, Educational 3Cyclophosphamide 3Celecoxib 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2relatlimab 2pertuzumab 2palbociclib 2durvalumab 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × 90 days × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡